NCT06329674View on ClinicalTrials.gov

Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

June 13, 2023

Conditions
Type2 Diabetes
Interventions
DRUG

AJU-A51

Subjects take the investigational products once a day for 24 weeks.

DRUG

A51R2

Subjects take the investigational products once a day for 24 weeks.

DRUG

A51R3

Subjects take the investigational products once a day for 24 weeks.

DRUG

AJU-A51 Placebo

Subjects take the investigational products once a day for 24 weeks.

DRUG

A51R2 Placebo

Subjects take the investigational products once a day for 24 weeks.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

AJU Pharm Co., Ltd.

INDUSTRY